Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PDIA3 correlates with clinical malignant features and immune signature in human gliomas.

Aging - 29 Aug 2020

Zhang Hao, Zhou Yulai, Cheng Quan, Dai Ziyu, Wang Zeyu, Liu Fangkun, Fan Fan, Cui Biqi, Cao Hui

Abstract excerpt

Since therapeutic strategies are limited in gliomas, new molecules or biomarkers are essential for diagnosis and therapy. Here, we investigated expression of protein disulfide isomerase family A member 3 (PDIA3) in gliomas to evaluate its potential as a promising immune target or biomarker. Transcriptome level, genomic profiles and its association with clinical practice from TCGA and CGGA databases were analyzed....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Mutation

Share to Protein Disulfide-Isomerases

Source

Open in PubMed Open full text

Identifiers

PMID: 32687065
DOI: 10.18632/aging.103601
PMCID: PMC7467394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PDIA3 correlates with clinical malignant features and immune signature in human gliomas.PMID 32687065Read ↗

Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response EffectivelySemantic proximity Read ↗

P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.Semantic proximity Read ↗

FNDC3B is a Potential Prognostic Biomarker and Correlated With Immune Infiltrates in GliomaSemantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

DIRAS3 might function as a diagnostic biomarker and be related to immune infiltration in gliomasSemantic proximity Read ↗

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in GliomaSemantic proximity Read ↗

Comprehensive Analysis Reveals Promising Immune Target and Prognostic Value of PLK3 in GliomaSemantic proximity Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

The ALDH Family Contributes to Immunocyte Infiltration, Proliferation and Epithelial-Mesenchymal Transformation in GliomaSemantic proximity Read ↗

Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas.Semantic proximity Read ↗

Genetic and clinical characterization of B7‐H3 (CD276) expression and epigenetic regulation in diffuse brain gliomaSemantic proximity Read ↗

PD-1 related transcriptome profile and clinical outcome in diffuse gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.